On January 19th, Tony Abboud, the Executive Director of the Vapor Technology Association (VTA), announced that the U.S. Food and Drug Administration (FDA) has issued a Marketing Denial Order (MDO) for Suorin and blu PLUS+ e-cigarettes. This decision by the FDA and the Center for Tobacco Products (CTP) is seen as part of their ongoing efforts to effectively ban e-cigarettes in the United States.
Abdullah states that the FDA continually emphasizes that e-cigarette manufacturers have not provided "sufficient scientific evidence" in their PMTA applications. However, the FDA refuses to address the Reagan-Udall Foundation's fundamental criticism of the entire regulatory process, which is that the FDA has not clearly outlined what needs to be proven for something to be considered "appropriate for the protection of public health (APPH)," nor how it interprets what APPH entails.
Abdul believes that not objectively defining and using standards to refuse marketing authorization for critical smoking cessation and harm reduction products is a serious overreach for any government agency that follows a scientific mission.
The court found that the process had become "arbitrary and capricious" in practice, with CTP leadership determining standards based on specific circumstances. Meanwhile, the company was simply attempting to do the right thing by adhering to the PMTA process established by the FDA.
He continued, "Most notably, CTP claims to have denied Suorin's PMTA because its product promotes 'sustained use and progression' of dependence. If this is the standard, then every nicotine product would fail CTP's bizarre criteria, as nicotine is addictive, furthering CTP's implementation of a ban on less harmful nicotine."
"The actions taken by the FDA and CTP today do not contribute to the protection of public health or to assisting Americans who smoke. VTA once again urges CTP to reverse its malicious behavior and restore the scientific integrity of its regulatory and decision-making processes. Enough is enough," said Abdu.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
